MedTrace Logo

Empower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial

NCT05636774 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2025-08-22

No results posted yet for this study

Summary

The pathophysiological implications of various cancer diseases and anti-cancer therapies is the occurrence of a cardiac disease-like phenotype with cardiac dysfunction, cardiac wasting, and cardiac homeostasis changes (incl. fibrosis and apoptosis) in end-stage cancer patients, causing heart failure like syndrome with development of congestion, dyspnoea and severely reduced physical functioning. The present trial aims to evaluate, if a heart failure medication improves the self-care ability and self-reported health care status of patients with with advanced cancer receiving specialized palliative care.

Conditions

  • Patients With Advanced Cancer Receiving Specialized Palliative Care

Interventions

DRUG

Heart failure medication

Combination of Sacubitril/valsartan, Ivabradine, Ferric carboxymaltose and/or Empagliflozin.

DRUG

Placebo

Placebo tables / infusion

Sponsors & Collaborators

  • Charite University, Berlin, Germany

    collaborator OTHER

  • Universitätsklinikum Leipzig

    collaborator OTHER

  • University Hospital Heidelberg

    collaborator OTHER

  • University Hospital Homburg/Saar

    collaborator UNKNOWN

  • University Hospital, Essen

    lead OTHER

Principal Investigators

  • Tienush Rassaf, MD · University Hospital, Essen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-12
Primary Completion
2025-01-31
Completion
2025-03-01

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05636774 on ClinicalTrials.gov